TAXUS(R) Express(R) Stent Shows Similarly Low Re-Intervention Rates in Patients With Diabetes Compared to Non-Diabetics in Arrive Regist...(s and repeat stenting procedures said D...),Health

The growing diabetic subset accounts for more than one-quarter of all coronary interventional procedures in the United States. Diabetes is generally associated with an increased risk of overall mortality and cardiovascular events. In addition, patients with diabetes are more likely than non-diabetic patients to require repeat procedures due to a higher incidence of restenosis following angioplasty and stenting.

In the United States, the TAXUS Stent is not specifically indicated for use in patients with diabetes.

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: http://www.bostonscientific.com.

(1) The higher-risk group includes the following patient and lesion

characteristics: vein graft, left main, bifurcation, severe

calcification, cardiogenic shock, direct stenting of total occlusion,

thrombus, severely tortuous vessels, total stent length >64mm, which

are outside approved indications. The lower-risk group excludes these

patient and lesion characteristics. Indications, contraindications,

warnings, precautions and instructions for use can be found in the

product labeling supplied with each device.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe,
'/>"/>